This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.
Check your eligibility (clinicaltrials.gov)
Participate in a Clinical Trial at Saint John’s Cancer Institute.
Questions regarding this trial: 818-748-4772